ABSTRACT
UNLABELLED: BACKGROUND. Ribavirin is active in vitro against hantaviruses, but the findings of an open trial of the use of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome (HCPS) were inconclusive. METHODS: Subjects with suspected HCPS in the prodrome or cardiopulmonary phase but without shock were eligible for randomization to receive either intravenous ribavirin (33 mg/kg [Subject(s)
Antiviral Agents/administration & dosage
, Antiviral Agents/therapeutic use
, Hantavirus Pulmonary Syndrome/drug therapy
, Ribavirin/administration & dosage
, Ribavirin/therapeutic use
, Adult
, Antiviral Agents/adverse effects
, Double-Blind Method
, Female
, Hantavirus Pulmonary Syndrome/mortality
, Humans
, Injections, Intravenous
, Male
, Middle Aged
, North America/epidemiology
, Placebos
, Ribavirin/adverse effects